Molnupiravir has been shown to prevent serious illness and death, although it is still in late stage clinical trials
- Follow our Covid live blog for the latest updates
- Australia cases and data tracker;
- Get our free news app; get our morning email briefing
Australia has secured 300,000 courses of molnupiravir, an antiviral capsule to treat Covid-19 that could be in use by early 2022.
The Morrison government has struck a supply agreement with MSD to provide the oral treatment if it is approved by the Therapeutic Goods Administration.
Read the original article at The Guardian